STOCK TITAN

LabCorp Is Scheduled to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

LabCorp (NYSE: LH) will participate in a virtual fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Monday, Nov. 9, at 8:00 a.m. ET. This event will feature members of the executive management team discussing key topics in healthcare. A live audio webcast of the presentation will be available on www.LabCorp.com and will be archived for later access. As a leading life sciences company, LabCorp is dedicated to improving health and advancing patient care, reporting over $11.5 billion in revenue in 2019.

Positive
  • None.
Negative
  • None.

BURLINGTON, N.C.--()--LabCorp (NYSE: LH) today announced that members of the executive management team will participate in a virtual fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Monday, Nov. 9 at 8:00 a.m. ET.

A live audio webcast of the presentation will be available via the company website at www.LabCorp.com and archived for replay.

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11.5 billion in 2019.

To learn more about LabCorp, visit www.LabCorp.com, and to learn more about LabCorp’s drug development business, Covance, visit www.Covance.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements with respect to the impact of various factors on operating and financial results and the opportunities for future growth. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, the impact of the COVID-19 pandemic on our business and financial condition as well as on general economic, business, and market conditions, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, the Company’s satisfaction of regulatory and other requirements, patient safety issues, changes in testing guidelines or recommendations, federal, state, and local governmental responses to the COVID-19 pandemic, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, changes in business conditions and the economy in general, adverse weather conditions, the number of revenue days in a financial period, employee relations, personnel costs, and effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.

# # #

Contacts

LabCorp Contacts:
Investors: Clarissa Willett - 336-436-5076
Investor@LabCorp.com

Media: Donald Von Hagen - 336-436-8263
Media@LabCorp.com

FAQ

What is LabCorp's participation in the Credit Suisse Virtual Healthcare Conference?

LabCorp will participate in a virtual fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Nov. 9, at 8:00 a.m. ET.

Where can I watch the LabCorp conference presentation?

The conference presentation can be watched live on LabCorp's website at www.LabCorp.com.

What revenue did LabCorp report in 2019?

LabCorp reported revenue of over $11.5 billion in 2019.

When is the LabCorp conference scheduled?

The LabCorp conference is scheduled for Monday, Nov. 9, at 8:00 a.m. ET.

What is LabCorp's main mission as a company?

LabCorp's mission is to improve health and improve lives through comprehensive clinical laboratory and drug development services.

Labcorp Holdings Inc.

NYSE:LH

LH Rankings

LH Latest News

LH Stock Data

20.17B
83.32M
0.33%
95.07%
2.67%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
BURLINGTON